GSK Follows Rivals, to Cap Out-of-Pocket Inhaler Cost in US

Mar 21, 2024 · TEVA. GSK plc GSK announced plans to cap out-of-pocket expenses for its …

CouponFollow Extension

$35
OFF

GSK Announces Cap Of $35 Per Month On U.S. Patient Out-of …

2 weeks from now

Mar 20, 2024 · Announcement builds on GSK’s decades-long commitment to making products …

gsk.com

$35
OFF

GSK Joins AstraZeneca, Boehringer In Capping US Out-of-pocket …

2 weeks from now

Mar 21, 2024 · Each drugmaker is capping out-of-pocket costs at $35 per month for their …

fiercepharma.com

$35
OFF

GSK To Cap Asthma, COPD Inhaler Costs To $35 Per Month For …

2 weeks from now

Mar 25, 2024 · GSK to Cap Asthma, COPD Inhaler Costs to $35 Per Month for Eligible …

pulmonologyadvisor.com

$35
OFF

These Inhalers No Longer Cost More Than $35 Per Month

2 weeks from now

Mar 26, 2024 · Amidst untenable drug prices, there's finally some good news: Several …

verywellhealth.com

$35
OFF

GSK Announces Cap Of $35 Per Month On U.S. Patient Out-of …

2 weeks from now

Mar 20, 2024 · GSK today announced it will cap out-of-pocket costs for eligible patients at no …

industryintel.com

FAQs about GSK Follows Rivals, to Cap Out-of-Pocket Inhaler Cost in US Coupon?

Will GSK cap out-of-pocket expenses for its inhaled respiratory portfolio?

GSK plc GSK announced plans to cap out-of-pocket expenses for its inhaled respiratory portfolio in the United States at $35 per month, following a similar move by rivals AstraZeneca AZN and Boehringer Ingelheim earlier this month. ...

What is the GSK out-of-pocket price cap?

The out-of-pocket price cap will provide a significant benefit to patients taking these medicines whose monthly costs currently exceed $35. Maya Martinez-Davis, President, U.S. Commercial, GSK said: “GSK is committed to bringing innovation and accessibility to patients with respiratory illnesses. ...

Is GSK capping patients' monthly payments for COPD Meds?

(GlaxoSmithKline) Amid congressional scrutiny on U.S. inhaler prices, GSK is the latest pharma giant to commit to capping patients' monthly payments for its portfolio of asthma and chronic obstructive pulmonary disease (COPD) meds. The move follows similar announcements from GSK's peers Boehringer Ingelheim and AstraZeneca. ...

Are pharmaceutical companies capping out-of-pocket inhalers at $35?

Amidst untenable drug prices, there's finally some good news: Several pharmaceutical companies are capping the out-of-pocket price of select inhalers at $35. GlaxoSmithKline (GSK) is the latest company to announce a price cap this month, following the lead of AstraZeneca and Boehringer Ingelheim, who revealed their inhaler price ceilings in March. ...

How much does GSK cost per month?

GSK plc (GSK) plans to lower the prices of its entire inhaled respiratory products to $35 per month in the United States. The company intends to start this in 2025. ...

Does GSK have a COPD cap?

This cap would apply to all of GSK’s asthma and chronic obstructive pulmonary disease (COPD) inhalers, which include Advair Diskus, Advair HFA, Anoro Ellipta, Breo Ellipta and Trelegy Ellipta. However, GSK plans to start this in 2025. The British drugmaker is one of the biggest sellers of inhalers in the United States. ...